Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1.

Weekes D, Kashima TG, Zandueta C, Perurena N, Thomas DP, Sunters A, Vuillier C, Bozec A, El-Emir E, Miletich I, Patiño-Garcia A, Lecanda F, Grigoriadis AE.

Oncogene. 2016 Jun 2;35(22):2948. doi: 10.1038/onc.2015.420. No abstract available.

PMID:
27251742
2.

Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1.

Weekes D, Kashima TG, Zandueta C, Perurena N, Thomas DP, Sunters A, Vuillier C, Bozec A, El-Emir E, Miletich I, Patiño-Garcia A, Lecanda F, Grigoriadis AE.

Oncogene. 2016 Jun 2;35(22):2852-61. doi: 10.1038/onc.2015.344. Epub 2015 Sep 21. Erratum in: Oncogene. 2016 Jun 2;35(22):2948.

3.

Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial.

Brill SE, Law M, El-Emir E, Allinson JP, James P, Maddox V, Donaldson GC, McHugh TD, Cookson WO, Moffatt MF, Nazareth I, Hurst JR, Calverley PM, Sweeting MJ, Wedzicha JA.

Thorax. 2015 Oct;70(10):930-8. doi: 10.1136/thoraxjnl-2015-207194. Epub 2015 Jul 15.

4.

Community-based recruitment of patients with COPD into clinical research.

Brill SE, El-Emir E, Allinson JP, Donaldson GC, Nazareth I, Wedzicha JA.

Thorax. 2014 Oct;69(10):951-2. doi: 10.1136/thoraxjnl-2014-205253. Epub 2014 Mar 4.

5.

A one-pot three-component radiochemical reaction for rapid assembly of 125I-labeled molecular probes.

Yan R, Sander K, Galante E, Rajkumar V, Badar A, Robson M, El-Emir E, Lythgoe MF, Pedley RB, Årstad E.

J Am Chem Soc. 2013 Jan 16;135(2):703-9. doi: 10.1021/ja307926g. Epub 2013 Jan 7.

PMID:
23194416
6.

Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression.

Yang J, Staples O, Thomas LW, Briston T, Robson M, Poon E, Simões ML, El-Emir E, Buffa FM, Ahmed A, Annear NP, Shukla D, Pedley BR, Maxwell PH, Harris AL, Ashcroft M.

J Clin Invest. 2012 Feb;122(2):600-11. doi: 10.1172/JCI58780. Epub 2012 Jan 3.

7.

One-pot synthesis of an 125I-labeled trifunctional reagent for multiscale imaging with optical and nuclear techniques.

Yan R, El-Emir E, Rajkumar V, Robson M, Jathoul AP, Pedley RB, Årstad E.

Angew Chem Int Ed Engl. 2011 Jul 18;50(30):6793-5. doi: 10.1002/anie.201102072. Epub 2011 Jun 14. No abstract available.

PMID:
21674741
8.

Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy.

Fidarova EF, El-Emir E, Boxer GM, Qureshi U, Dearling JL, Robson MP, Begent RH, Trott KR, Pedley RB.

Clin Cancer Res. 2008 May 1;14(9):2639-46. doi: 10.1158/1078-0432.CCR-07-2031.

9.

Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas.

El Emir E, Qureshi U, Dearling JL, Boxer GM, Clatworthy I, Folarin AA, Robson MP, Nagl S, Konerding MA, Pedley RB.

Cancer Res. 2007 Dec 15;67(24):11896-905.

10.

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.

El-Emir E, Dearling JL, Huhalov A, Robson MP, Boxer G, Neri D, van Dongen GA, Trachsel E, Begent RH, Pedley RB.

Br J Cancer. 2007 Jun 18;96(12):1862-70. Epub 2007 May 22.

11.

Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down.

Lankester KJ, Maxwell RJ, Pedley RB, Dearling JL, Qureshi UA, El-Emir E, Hill SA, Tozer GM.

Int J Oncol. 2007 Feb;30(2):453-60.

PMID:
17203228
12.

Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice.

El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, Pedley RB.

Eur J Cancer. 2005 Mar;41(5):799-806.

PMID:
15763657
13.

Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.

Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U, Tolner B, Lowe H, Michael NP, Minton N, Begent RH, Chester KA.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):814-25.

14.

The nonuniformity of antibody distribution in the kidney and its influence on dosimetry.

Flynn AA, Pedley RB, Green AJ, Dearling JL, El-Emir E, Boxer GM, Boden R, Begent RH.

Radiat Res. 2003 Feb;159(2):182-9.

PMID:
12537523
15.

Synergy between vascular targeting agents and antibody-directed therapy.

Pedley RB, El-Emir E, Flynn AA, Boxer GM, Dearling J, Raleigh JA, Hill SA, Stuart S, Motha R, Begent RH.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1524-31.

PMID:
12459381
16.

Spatial accuracy of 3D reconstructed radioluminographs of serial tissue sections and resultant absorbed dose estimates.

Petrie IA, Flynn AA, Pedley RB, Green AJ, El-Emir E, Dearling JL, Boxer GM, Boden R, Begent RH.

Phys Med Biol. 2002 Oct 21;47(20):3651-61.

PMID:
12433126

Supplemental Content

Loading ...
Support Center